These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines]. Manzeniuk IN; Galina EA; Dorokhin VV; Kalachev IIa; Borzenkov VN; Svetoch EA Antibiot Khimioter; 1999; 44(6):21-6. PubMed ID: 10422574 [TBL] [Abstract][Full Text] [Related]
5. [Pathogenicity of Burkholderia pseudomallei: extracellular and surface antigen functions]. Piven' NN; Iliukhin VI Zh Mikrobiol Epidemiol Immunobiol; 2000; (6):94-9. PubMed ID: 11210655 [TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of and immunity to melioidosis. Brett PJ; Woods DE Acta Trop; 2000 Feb; 74(2-3):201-10. PubMed ID: 10674650 [TBL] [Abstract][Full Text] [Related]
7. Lipopolysaccharide from nonvirulent Ara+ Burkholderia pseudomallei isolates is immunologically indistinguishable from lipopolysaccharide from virulent Ara- clinical isolates. Anuntagool N; Intachote P; Wuthiekanun V; White NJ; Sirisinha S Clin Diagn Lab Immunol; 1998 Mar; 5(2):225-9. PubMed ID: 9521147 [TBL] [Abstract][Full Text] [Related]
8. Immunoblot analysis to demonstrate antigenic variability of clinical isolated. Pseudomonas pseudomallei. Lertmemongkolchai G; Manmontri W; Leelayuwat C; Romphruk A; Waropastrakul S Asian Pac J Allergy Immunol; 1991 Jun; 9(1):5-8. PubMed ID: 1723272 [TBL] [Abstract][Full Text] [Related]
9. Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. Warawa J; Woods DE FEMS Microbiol Lett; 2005 Jan; 242(1):101-8. PubMed ID: 15621426 [TBL] [Abstract][Full Text] [Related]
10. Virulence of the Melioidosis Pathogen Burkholderia pseudomallei Requires the Oxidoreductase Membrane Protein DsbB. McMahon RM; Ireland PM; Sarovich DS; Petit G; Jenkins CH; Sarkar-Tyson M; Currie BJ; Martin JL Infect Immun; 2018 May; 86(5):. PubMed ID: 29440370 [TBL] [Abstract][Full Text] [Related]
11. [Immunogenic potential of glanders and melioidosis agents]. Kalachev II; Baídus' AN; Ivanova OA; Ganina EA; Boldyrev IA; Svetoch EA Vestn Ross Akad Med Nauk; 1997; (6):32-7. PubMed ID: 9289277 [TBL] [Abstract][Full Text] [Related]
16. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. DeShazer D; Brett PJ; Woods DE Mol Microbiol; 1998 Dec; 30(5):1081-100. PubMed ID: 9988483 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays. Welkos SL; Klimko CP; Kern SJ; Bearss JJ; Bozue JA; Bernhards RC; Trevino SR; Waag DM; Amemiya K; Worsham PL; Cote CK PLoS One; 2015; 10(4):e0124667. PubMed ID: 25909629 [TBL] [Abstract][Full Text] [Related]
18. Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. Rodrigues F; Sarkar-Tyson M; Harding SV; Sim SH; Chua HH; Lin CH; Han X; Karuturi RK; Sung K; Yu K; Chen W; Atkins TP; Titball RW; Tan P J Bacteriol; 2006 Dec; 188(23):8178-88. PubMed ID: 16997946 [TBL] [Abstract][Full Text] [Related]